Florence A. Rothman Institute
1803 Glengary Street
Sarasota FL 34231
Improve healthcare delivery by performing and supporting research to develop and utilize innovative approaches to the analysis and interpretation of medical data.
CEO/Executive Director Dr George Duncan Finlay JR
Board Chair G. Duncan Finlay M.D.
Board Chair Affiliation AliveScience, LLC
General Info
Organization DBA
The Florence A. Rothman Institute
Tax Exempt Status Public Supported Charity
Incorporation Year 2012
Awarded competitive grant from Community Foundation in the last 5 years? No
State Charitable Solicitations Permit Yes July 2018
State Registration 0
Financial Summary
Note: Revenue includes the value of in-kind contributions/donations
IRS Letter of Determination
IRS Letter of DeterminationView
Other Documents
Nondiscrimination policyView
Grant application processView
Impact Statement

Our current projects utilize the techniques developed by Steven and Michael Rothman and vary from exploring a new way of identifying patients with Alzheimer’s Disease before the onset of symptoms, establishing new reference limits for common laboratory tests, improving the Rothman Index, and reducing hospital readmissions to finding unique patterns in patients with multiple chronic diseases (particularly appropriate to our demographics).

Needs Statement
  1. Hire full-time PhD researcher: $120,000 annual salary.
  2. SAS statistical package annual license $1450. 
  3. Annual support for salaries for scientists: $412,000.00
Background Statement


Florence A. Rothman died a preventable death in 2003 following “successful” open-heart surgery.  Her sons, Steven and Michael Rothman, have devoted the last 10 years to helping patients and families avoid a similar experience. They developed and validated the Rothman Index, which uses data from the patient's electronic medical record (EMR) to provide an early warning of a downturn in health.  Now, in use in both acute and non-acute care settings, the Rothman Index provides valuable information to providers, patients and families.

Recognizing that a deeper understanding of a patient's EMR could help address other clinical issues, Steven Rothman established the Florence A. Rothman Institute (FARI), a not-for-profit 501c3 organization in Sarasota, Florida. Today, FARI conducts and supports medical research focusing on patient data, including analytic tools developed by the Rothmans.

By applying data science to medical conditions, FARI's researchers have published a groundbreaking study that validates the strong correlation of nursing assessments with mortality. Other studies include the value of risk-based decision-limits versus demographically standardized reference intervals for routine laboratory test results, and improved accuracy in identifying hospitalized patients who will undergo life-threatening clinical deterioration.

Currently, FARI is engaged in the Alzheimer Disease Initiative supported by grants from the Sarasota Memorial Healthcare Foundation and the New York Community Trust. The goal of this major project is to uncover new information on early detection and therapeutic approaches to Alzheimer’s disease and other dementias.  In addition, the FARI data science approach will contribute to building a “learning health system” that can leverage a patient's EMR to investigate clinical patterns and identify trends in acuity to provide timely actionable knowledge to improve patient care and safety.

Under the leadership of Rothman and G. Duncan Finlay, former CEO of Sarasota Memorial Hospital, FARI's future research projects include studies on the risks of mortality associated with patient diagnoses and clusters of diagnoses, as well as those associated with clusters of laboratory results. These innovative studies will be conducted in collaboration with other non-profit entities, such as hospitals, medical schools, and research institutions.


Areas Served
Areas Served
Areas Served Comments N/A
Service Categories
Primary Org Type Medical Research
Secondary Org Type Health Care
Tertiary Org Type Medical Research
Statement from the Board Chair/Board President
Statement from the CEO/Executive Director

As CEO of the Florence A Rothman Institute I am passionate about the possibilities for our organization to make major contributions to the knowledge and methods available to improve healthcare. We are truly unique in our position in healthcare research and it is exciting to be on the cutting edge of a new way to look at the data already present in the electronic medical records and transform that data into usable information. Our current initiative in the development of a novel way to detect and monitor Alzheimer’s disease is a perfect example of this approach. We are non-profit in the truest sense and raise funds only to support our research. Our team stands ready, with your help, to make a real difference.

Develop and Validate a Model to Identify Alzheimer’s Disease and other Dementias using Electronic Medical Record Data: A Feasibility Study
      Keywords: Alzheimer’s disease, Co-morbidity, Dementia, Electronic Medical Record, EMR data science, Mild Cognitive Impairment, Polymorbidity, Predictive model, Probabilistic classification, Retrospective cohort study, Risk scores
The FAR Institute is working to develop and validate a model that eventually can be used to identify patients with undiagnosed Alzheimer's Disease/dementia, or even Mild Cognitive Impairment (MCI).

Alzheimer’s disease is an escalating national epidemic. According to the Alzheimer’s Association:
• One in nine (11%) people aged 65 and older have AD.
• About one-third (32%) of people aged 85 and older have AD.
• Older African-Americans are twice as likely to suffer from aging-related dementia or Alzheimer’s as Caucasian counterparts.
• Hispanics are 1.5 times as likely to have AD.

Budget $75,000
Category Diseases, Disorders & Medical Disciplines, General/Other Alzheimer Disease
Program Linked to Organizational Strategy Yes
Population Served Aging, Elderly, Senior Citizens
Short Term Success
  • Gain a better understanding of the disease progression of Alzheimer's Disease and other dementias 
  • Identify medicines not prescribed for Alzheimer's Disease or dementia that may provide some protective effects.
Long Term Success

In the long term, this project has the potential for far-reaching impact as individuals, families and communities benefit from patients who are living longer without the devastating impact of Alzheimer's Disease and dementia.

Program Success Monitoring

Data management and quality control procedures have been developed and documented to ensure this project and its success are monitored.

Program Success Examples We may learn that long-term use of anti-inflammatory medicines (statins) may delay onset and/or severity of Alzheimer's Disease or dementia, for example. This will help the medical community do a better job of working with potential patients.
  • Proactive Patient ACuity sTewardship (PACT) trial
    • Keywords: patient acuity monitoring, patient safety, Rothman Index
Budget $75,000
Category Health Care, General/Other Quality of Health Care
Program Linked to Organizational Strategy Yes
Population Served Adults General/Unspecified US
Short Term Success Significant improvement in readmissions to the acute care hospitals, increased referrals to Palliative care, decreased re- admissions to the ICU. Engage patients in their own care and follow patient reported outcomes.  Establish a methodology for following and engaging patients at any level of care from the acute care hospital to independent living. 
Long Term Success We will document the effectiveness of the Rothman Index to improve the quality of care in the hospital, skilled nursing facility, assisted living and independent living setting.
Program Success Monitoring Measuring mortality, readmissions and quality of care for inpatients, skilled nursing facility residents, assisted living residents and independently living residents.
Program Success Examples Readmissions, patient satisfaction, standard quality metrics in SNFs
Data-driven Clinical Phenotyping of Hospitalized Patients with Multiple Chronic Conditions: A Natural EXperiment using Electronic Medical Records (MCC NatX Study).  Keywords: Multiple Chronic Conditions (MCC); Electronic Medical Records (EMR); Natural History Experiment
This study utilizes cutting edge data analytic techniques to discover information stored in Electronic Medical Records of hospitalized patients based on the theory that there are millions of "natural experiments" related to the treatment that has already occurred in acute care hospitals in patients with more than one chronic medical condition, i.e. the patient has been treated with a particular combination of drugs or surgical procedures and the outcome is know and is specific for this patient.  This is a first step in developing Precision or Personalized Medicine.
Budget $7,500
Category Health Care, General/Other Quality of Health Care
Program Linked to Organizational Strategy Yes
Population Served Adults General/Unspecified US
Short Term Success Acquiring and preparing the extremely large data base for analysis.
Long Term Success Publication of a series of scientific papers describing the findings of this program as well as the techniques available to other investigators.
Program Success Monitoring
Adoption of FARI data mining techniques.
Improve outcomes for hospitalized patients: patient and family satisfaction; improved mortality rates; decreased medical error rates and improved outcomes 
Program Success Examples No results to date
CEO/Executive Director
CEO/Executive Director Dr George Duncan Finlay JR
CEO Term Start Aug 2012
CEO/Executive Director Email duncan.finlay@farinstitute.org
Experience Practicing physician for 24 years, CEO Sarasota Memorial Healthcare System 2000-2005, CEO Rothman Healthcare Research, LLC 2008-2010; Board of Directors: Plymouth Harbor, Inc.  Previous Boards: Sarasota Memorial Health Care Foundation, SCOPE, United Way of Sarasota County, Community Foundation of Sarasota County,
Former CEOs/Executive Directors
Senior Staff
Staff & Volunteer Statistics
Full Time Staff 4
Part Time Staff 0
Staff Retention Rate % N/A
Professional Development Yes
Contractors 2
Volunteers 0
Management Reports to Board N/A
CEO/Executive Director Formal Evaluation N/A
Senior Management Formal Evaluation N/A
Non-Management Formal Evaluation N/A
FAR Institute collaborates with the Roskamp Institute, Sarasota Memorial Hospital, and PeraHealth, Inc., New College of Florida
External Assessments and Accreditations
Awards & Recognition
2015 Abstract Award for Outstanding Research in Medical InformaticsAmerican Association for Clinical Chemistry2015
Risk Management Provisions
Fundraising Plan No
Communication Plan No
Strategic Plan No
Strategic Plan Years
Strategic Plan Adopted 0
Management Succession Plan No
Continuity of Operations Plan
Nondiscrimination Policy Yes
Whistle Blower Policy Yes
Document Destruction Policy Yes
Directors and Officers Insurance Policy
Policies and Procedures No
Management Comments by Organization    
Board Chair
Board Chair G. Duncan Finlay M.D.
Company Affiliation AliveScience, LLC
Board Term Jan 2013 to Dec 2018
Board Chair Email duncan.finlay@farinstitute.org
Board Members
Board Members
Darlene Arbeit Alive Sciences, LLC
Janis Cohen Community Volunteer
G. Duncan Finlay M.D.Community Volunteer
Alan B. Grindal M.D.Community Volunteer
Steven Isaiah Rothman Community Volunteer
David Siegel M.D.Community Volunteer
Constituency Includes Client Representation No
Board Ethnicity
African American/Black 0
Asian American/Pacific Islander 0
Caucasian 6
Hispanic/Latino 0
Native American/American Indian 0
Other 0 0
Board Gender
Male 4
Female 2
Unspecified 0
Board Term Lengths 99
Board Term Limits 99
Board Orientation Yes
Number of Full Board Meetings Annually 3
Board Meeting Attendance % 80
Board Self-Evaluation Yes
Written Board Selection Criteria No
Board Conflict of Interest Policy Yes
% of Board Making Monetary Contributions 100
% of Board Making In-Kind Contributions 0
Governance Comments by Organization Our organization is not a fundraising organization--our focus is research. This is why board members do not contribute financially.
Current Year Projections
Tax Year Start Month Jan
Tax Year Start Day 01
Tax Year Begins 2018
Tax Year End Month Dec
Tax Year End Day 31
Tax Year Ends 2018
Projected Revenue $120,000.00
Projected Expenses $120,000.00
Total Projected Revenue includes "in-kind" contributions/ donations No
Organization has Endowment No
Endowment Spending Policy N/A
Capital Campaign
Currently In a Capital Campaign No
Campaign Purpose
Campaign Goal
Amount Raised To Date 0 as of 0
IRS Form 990s
Audit/Financial Documents
Financial Review
Expense Allocation
Fiscal Year201620152014
Program Expense$220,446$72,570$0
Administration Expense$18,674$2,307$0
Fundraising Expense$0$0$0
Payments to Affiliates$0$0$0
Total Revenue/Total Expenses1.010.69--
Program Expense/Total Expenses92%97%--
Fundraising Expense/Contributed Revenue0%0%--
Assets and Liabilities
Fiscal Year201620152014
Total Assets$54,978$33,807$28,964
Current Assets$54,978$33,807$28,964
Long-Term Liabilities$0$0$0
Current Liabilities$121,291$101,750$73,804
Total Net Assets($66,313)($67,943)($44,840)
Top Funding Sources
Fiscal Year201620152014
Top Funding Source & Dollar AmountContributions, gifts, grants $240,750Contributions, gifts, grants $51,7740 $0
Second Highest Funding Source & Dollar Amount0 $00 $00 $0
Third Highest Funding Source & Dollar Amount0 $00 $00 $0
CEO/Executive Director Compensation $0 - $50,000
Co-CEO/Executive Director Compensation N/A
Tax Credits No
Short Term Solvency
Fiscal Year201620152014
Current Ratio: Current Assets/Current Liabilities0.450.330.39
Long Term Solvency
Fiscal Year201620152014
Long-Term Liabilities/Total Assets0%0%0%
Financials Comments
Financial Comments by Foundation Financial information taken from Federal 990-EZ.  Contributions include foundation and corporate support.
Nonprofit Florence A. Rothman Institute
Address 1803 Glengary Street
Sarasota, FL 34231
Phone 941 525-3047